How to Vet a Canadian Psychedelic-Assisted Therapy Clinic: A Patient's Guide

Psychedelic-assisted therapy in Canada is a rapidly expanding field with highly variable provider quality. Some clinics are anchored in anesthesiology departments at academic teaching hospitals; others are pop-up storefronts using sublingual ketamine lozenges with minimal medical oversight. Both call themselves "psychedelic clinics." The off-label nature of most ketamine work, and the Special Access Program (SAP) basis for psilocybin and MDMA, means there is no single national license that separates one tier from the other. Patient diligence matters here in a way it does not for most other healthcare decisions. This guide is a Canadian, province-by-province framework for vetting a psychedelic-assisted therapy clinic before you book — including the specific provincial accreditation tiers that govern the room your medicine is administered in, 17 questions to ask before signing anything, and the red flags that should end a conversation.

Key takeaways

• Provincial regulatory frameworks govern psychedelic-assisted therapy clinics in Canada — there is no national license. The relevant body is the provincial College of Physicians and Surgeons (CPSO Ontario, CPSA Alberta, CPSBC British Columbia, CMQ Quebec, CPSS Saskatchewan, CPSM Manitoba).
• Accreditation tiers differ by route and province: Ontario CPSO OHPIP Levels I/II/III; Alberta CPSA NSHF for IV; BC NHMSFAP for IV; Saskatchewan CPSS NHTF for parenteral; Manitoba CPSM new framework January 2026.
• Spravato (esketamine) has its own pathway — Janssen Journey-certified clinics and locations.
• Psilocybin and MDMA in Canada are SAP-only. Any "at-home" psilocybin or MDMA outside SAP is not legitimate clinical practice.
• Seventeen questions in this guide cover medical leadership, accreditation, monitoring, screening, cost, insurance, and aftercare — the same questions a licensed clinical team welcomes from every prospective patient.
• Red flags include outcome promises, prominent testimonials, pressure to commit before clinical assessment, no integration phase, and misrepresentation of legal status (e.g., calling psilocybin "legal" outside SAP).

Why patient diligence matters in this field

Psychedelic-assisted therapy occupies an unusual regulatory position in Canada. Three patterns make patient vetting more important than it is in most healthcare decisions:

1. Most clinical work is off-label. IV, IM, sublingual, and oral ketamine are off-label psychiatric uses of a Health Canada-approved anaesthetic. Off-label prescribing is legitimate and well-established under Canadian off-label prescribing principles, but it places clinical judgment, screening rigour, and safety infrastructure on the clinic rather than on a label-driven monitoring requirement.
2. Psilocybin and MDMA are SAP-only. Health Canada's Special Access Program is the only legitimate clinical pathway for psilocybin and MDMA in Canada. Any provider offering "at-home" psilocybin or MDMA outside SAP is operating outside the legal clinical framework.
3. Provider quality is genuinely variable. A provincially accredited Non-Sedation Health Facility staffed by an anesthesiologist with a psychiatric clinical reviewer is in a different category from a storefront sublingual lozenge clinic with no medical director on premises. Both can call themselves "psychedelic clinics." The patient often cannot tell the difference from a website.

Vetting is not skepticism for its own sake. It is the same diligence you would apply to choosing a surgeon or a fertility clinic — and it is welcomed by reputable providers. A clinic that does not want to answer the questions in this guide is itself a data point.

Provincial regulatory frameworks: the map

Most accreditation that matters for a psychedelic-assisted therapy clinic is provincial, not federal. The relevant body is the provincial College of Physicians and Surgeons. Each province has its own framework for non-hospital medical facilities where parenteral medications, IV procedures, or sedation are administered.

Ontario — CPSO OHPIP

The College of Physicians and Surgeons of Ontario operates the Out-of-Hospital Premises Inspection Program (OHPIP) for facilities where members provide procedures involving anaesthesia or sedation outside hospital settings. OHPIP has tiered levels:

• Level I — minimal sedation
• Level II — moderate sedation / IV procedures, including IV ketamine
• Level III — deep sedation / general anaesthesia

For an Ontario clinic offering IV ketamine, OHPIP Level II accreditation is the relevant tier. Ask explicitly. "We are inspected by CPSO" is not the same as "we are OHPIP Level II accredited for IV procedures."

Alberta — CPSA NSHF

The College of Physicians and Surgeons of Alberta operates the Non-Sedation Health Facility (NSHF) Standards, which is the relevant accreditation for an Alberta clinic offering IV ketamine without general anaesthesia. CPSA also operates separate accreditation for sedation- and anaesthesia-level facilities. For Alberta IV ketamine specifically, NSHF accreditation is the patient-facing question to ask.

British Columbia — CPSBC NHMSFAP

The College of Physicians and Surgeons of British Columbia operates the Non-Hospital Medical and Surgical Facilities Accreditation Program (NHMSFAP), which governs out-of-hospital facilities providing IV procedures including IV ketamine. NHMSFAP accreditation is the BC-specific tier to ask about.

Quebec — CMQ

The Collège des médecins du Québec governs out-of-hospital medical facilities in Quebec under its own provincial framework. Quebec's RAMQ-funded SAP psilocybin pathway (the Farzin/Stephan precedent for end-of-life distress) is administered separately through provincial drug-funding mechanisms, but clinical facility standards remain under CMQ.

Saskatchewan — CPSS NHTF

The College of Physicians and Surgeons of Saskatchewan operates the Non-Hospital Treatment Facility (NHTF) framework, which covers parenteral medication administration including IV ketamine in Saskatchewan.

Manitoba — CPSM new framework January 2026

The College of Physicians and Surgeons of Manitoba is implementing a new accreditation framework for non-hospital facilities effective January 2026. Manitoba clinics offering IV ketamine should be familiar with this framework and its implementation timeline.

These tiers govern the room the medicine is administered in. They are necessary but not sufficient — accreditation does not on its own guarantee clinical quality, and absence of provincial accreditation for a clinic offering IV ketamine is a hard signal.

Spravato (esketamine): a separate pathway

Spravato is Health Canada-approved for treatment-resistant depression (Notice of Compliance May 2020) and operates under a label-mandated in-clinic monitoring framework. The patient-facing accreditation question for Spravato is whether the clinic is Janssen Journey-certified at the specific location you would attend. Janssen Journey is the manufacturer's distribution and clinical-training framework; it is location-specific, not corporate-wide. A clinic chain may have one Journey-certified location and several others that are not yet certified.

Ask: "Is this specific location Janssen Journey-certified for Spravato?" Not just "Does your group offer Spravato?"

For deep-dive: Spravato Coverage — PSHCP and Canada Life.

Seventeen questions to ask a clinic before booking

These questions are not a stress test. They are the questions ATMA CENA — and reputable Canadian clinics generally — expect from every prospective patient. Bring this list to your information call.

Medical leadership and accreditation

1. "What is your medical director's specialty — anesthesiology, psychiatry, family medicine?" This is the single most informative question. Anesthesiology backgrounds are common in IV-route ketamine clinics; psychiatry backgrounds are common in Spravato and KAP-psychotherapy programs; family medicine is common in lower-acuity sublingual or oral protocols. Each is legitimate in the right configuration, but the medical director's specialty should match the route and clinical model.

2. "Are you provincially accredited? Specifically, [the right accreditation tier for your province and your route]?" For Ontario IV: OHPIP Level II. For Alberta IV: CPSA NSHF. For BC IV: NHMSFAP. For Saskatchewan parenteral: CPSS NHTF. For Manitoba: CPSM (new framework January 2026). For sublingual or oral routes the accreditation requirements differ; ask what applies.

3. "Are you Janssen Journey-certified for Spravato? At which specific locations?" Location-specific, not corporate-wide.

Substance and route

4. "For off-label ketamine — what's your route? IV, IM, sublingual, or oral?" Each route has different pharmacology, safety profile, monitoring requirement, and accreditation implication. A clinic should be able to articulate why their chosen route fits their model.

5. "For psilocybin — this is SAP pathway only. Do you support SAP applications, and what's your role in the application process?" Any answer that involves "we have psilocybin available outside SAP" is disqualifying. Legitimate SAP psilocybin runs through a prescribing physician who submits the application to Health Canada. See The Health Canada SAP Application Process — Complete Guide.

6. "For MDMA-assisted therapy — this is SAP pathway only. Do you support SAP applications?" Same framework as psilocybin. MDMA outside SAP is not legitimate clinical practice in Canada.

Clinical model

7. "What's your three-phase model — preparation, dosing, integration? How is each phase structured?" A clinic should be able to walk you through preparation session counts, dosing-room protocols, and integration timing without hesitation. See The Preparation Phase of Psychedelic-Assisted Therapy.

Safety and monitoring

8. "What vitals are monitored during dosing — heart rate, blood pressure, oxygen saturation? Is monitoring continuous?" For IV ketamine and Spravato, continuous vitals monitoring during the active phase is standard. For sublingual or oral ketamine the monitoring intensity varies; ask specifically what is measured and when.

9. "Is your team ACLS-certified? Is there a crash cart on premises?" Advanced Cardiac Life Support certification for the clinical team and an on-premises crash cart are baseline expectations for any clinic administering IV or IM ketamine. Ask directly.

10. "What is your allergy and anaphylaxis protocol?" Epinephrine on-premises, written protocol, training cadence.

Screening

11. "What's your safety screening for personal and family history of psychotic disorders?" Personal history of psychotic disorders is generally an absolute contraindication for psilocybin and MDMA; first-degree relative family history is a strong relative contraindication. Ketamine has a different evidence profile but psychotic-disorder screening is still part of any reputable intake.

12. "What's your screening for bipolar disorder, eating disorder, and cardiovascular conditions?" These are the screening categories that distinguish a comprehensive intake from a perfunctory one. Ask which validated instruments and which clinical interview structure are used.

Licensure and continuity

13. "Is your clinical reviewer or medical director licensed to practice in [your province]?" Telehealth-only providers operating across provinces should hold provincial licensure for each province they prescribe in. Verify on the relevant College's public register.

Cost and insurance

14. "What's the cost per session, and what's the total program cost?" Get the full picture: intake, preparation sessions, dosing sessions, integration sessions, medication, monitoring time. Total program cost varies substantially. See ranges in Insurance Coverage for Psychedelic-Assisted Therapy in Canada.

15. "Insurance pathways — do you support prior authorization submission?" For Spravato specifically, prior auth submission is a substantial administrative effort and a clinic that handles it for you saves weeks. PSHCP, Manulife, Sun Life, Green Shield are the principal pathways.

Continuity of care

16. "How do you coordinate with my existing therapist or psychiatrist?" ATMA CENA's coordinated care model is built specifically for this — your existing therapist stays primary and the psychedelic-assisted therapy is layered on top. Ask any clinic how their model handles existing therapeutic relationships. See ATMA CENA's coordinated care model.

17. "What does aftercare and integration look like? How long, how many sessions, and is it included or separate cost?" Integration is the third phase of psychedelic-assisted therapy and is non-skippable clinical work. A clinic that frames integration as optional or "available if you want it" has not internalized the evidence base.

Red flags

Any one of the following should end a conversation, not start a negotiation.

Outcome promises

A clinic that tells you "we'll cure your depression" or "this will fix your PTSD" is making claims that no reputable provider in this field would make. Response rates in the strongest evidence — Goodwin 2022 COMP001 25 mg psilocybin in TRD — are 37% response, 29% remission at week 3. That is meaningful but not universal. Outcome promises are a College-level professional-conduct issue and a hard signal of provider quality.

Prominent testimonials

Patient testimonials in healthcare advertising are restricted under most provincial Medicine Acts and College advertising standards. A clinic that fronts its website with patient testimonials is operating outside professional advertising guidelines. Reputable Canadian clinics do not use testimonials regardless of how compelling individual patient experiences are.

Unsupervised "at-home" psilocybin or MDMA

Psilocybin and MDMA in Canada are accessible only via Health Canada's Special Access Program. SAP psilocybin and MDMA are administered under direct clinical supervision in prepared therapeutic settings. Any provider offering "at-home" psilocybin or MDMA outside SAP is operating outside the legal clinical framework. This is unambiguous.

No medical screening

A clinic that does not require comprehensive medical and psychiatric history before booking is skipping the most important clinical work in the model. Screening exists to prevent harm. A program that frames screening as optional is not a clinical program.

Pressure to commit before clinical assessment

Sales pressure, deposits required before intake, "limited spots this month" framing — these are commercial tactics from outside healthcare. Clinical decisions in psychedelic-assisted therapy belong with a prescribing physician after assessment, not with a sales funnel.

No integration phase

Integration is the third phase of psychedelic-assisted therapy. A clinic that offers dosing without integration is offering medication administration, not psychedelic-assisted therapy. The Goodwin 2022 COMP001 protocol, the Mitchell 2021/2023 MAPP1/MAPP2 MDMA protocols, and KAP literature including Dore 2019 and Mathai 2023 all build in structured integration.

Misrepresentation of legal status

A clinic that calls psilocybin "legal" outside SAP, or MDMA "approved in Canada," is misrepresenting the regulatory situation. Psilocybin is Schedule III and MDMA is Schedule I under the Controlled Drugs and Substances Act; clinical access is via SAP on a case-by-case basis. Spravato is Health Canada-approved for TRD; ketamine is approved as an anaesthetic and used off-label psychiatrically. Anything else is misrepresentation.

Mismatched provider and route

A non-anesthesiology clinic offering IV ketamine without provincial NSHF/NHMSFAP/OHPIP accreditation is a structural mismatch. The route (IV) and the accreditation (provincial out-of-hospital facility tier) and the provider specialty (anesthesiology or psychiatry with anaesthesia training) should align.

Public hospital ketamine programs as comparison

For TRD patients with the time and clinical pathway to access them, publicly funded outpatient psychiatric ketamine programs at academic hospitals are a useful comparison point on quality. The two best-known Canadian programs:

• Edmonton — Misericordia Community Hospital and Grey Nuns Community Hospital operate publicly funded outpatient psychiatric ketamine programs through the Mental Health Care Pathway. See Edmonton Misericordia/Grey Nuns Public Ketamine.
• Vancouver — UBC Hospital, Vancouver Coastal Health operates a publicly funded ketamine program for TRD.

Both programs are provincially funded, have psychiatric medical leadership, and are embedded in academic teaching hospitals. They establish a quality benchmark — the standard a private clinic should be able to meet or exceed in clinical infrastructure, even where private clinics differ in throughput, scheduling flexibility, and integration support.

ATMA CENA's commitment to transparency

ATMA CENA's clinical model is built to answer every question in this guide on the information call, on the record, before any commitment. Specifically:

• Provincial accreditation status for each ATMA CENA location is disclosed on intake — OHPIP, NSHF, NHMSFAP, NHTF, CMQ, or CPSM as applicable.
• Medical director specialty and clinical reviewer credentials are named, not hidden behind "our team."
• Three-phase model — preparation + dosing + integration — is the operating frame across all substances.
• Coordinated care — ATMA CENA layers on top of your existing therapeutic relationship rather than replacing it.
• No outcome promises and no testimonials — ATMA CENA's compliance posture follows Canadian College advertising standards.
• SAP pathway — for psilocybin and MDMA, ATMA CENA supports SAP applications submitted by prescribing physicians; nothing is offered outside SAP.

For pathway detail across substances see Psilocybin Therapy in Canada, Ketamine Therapy in Canada, and MDMA-Assisted Therapy in Canada.

Frequently asked questions

Is there a national accreditation that covers psychedelic-assisted therapy clinics in Canada? No. There is no single national license. Accreditation is provincial, through the relevant College of Physicians and Surgeons. The applicable tier depends on your province and the route (IV, IM, SL, oral, intranasal Spravato).

What's the difference between OHPIP, NSHF, NHMSFAP, and NHTF? They are the provincial accreditation frameworks for non-hospital facilities providing parenteral or sedation procedures. OHPIP is Ontario (CPSO); NSHF is Alberta (CPSA); NHMSFAP is BC (CPSBC); NHTF is Saskatchewan (CPSS). Each governs the room IV ketamine is administered in.

Does my clinic need accreditation if they only offer sublingual or oral ketamine? The accreditation requirements for sublingual or oral protocols differ from IV. Sublingual and oral routes have different pharmacokinetic profiles and lower acute monitoring requirements. The clinic should still be able to articulate which provincial framework governs their model.

Is "Janssen Journey-certified" the same as Health Canada-approved? No. Spravato is Health Canada-approved for TRD as a medication. Janssen Journey is the manufacturer's clinical-training and distribution framework that certifies specific clinic locations to administer Spravato under the label-mandated in-clinic monitoring requirement. Both are relevant; they are different things.

What if my province has no clinics with the relevant accreditation tier? This happens — particularly in Atlantic provinces and the territories. Options include: provincially licensed providers offering sublingual or oral protocols where accreditation requirements differ; telehealth-supported pathways with the prescribing physician licensed in your province; or travel to an accredited clinic in a neighbouring province. The coordinated care model accommodates blended pathways.

Can I ask to see the accreditation certificate? Yes. Provincial College accreditation is a matter of public record and reputable clinics will display or provide it on request. The provincial College's public register also lists physician licensure status.

What if a clinic refuses to answer these questions? That is itself a data point. A clinic confident in its clinical infrastructure will welcome these questions. A clinic that frames them as adversarial is telling you something important.

How do I report a clinic that is misrepresenting itself? Complaints about physician conduct go to the relevant provincial College of Physicians and Surgeons. Complaints about advertising of unapproved substances or products go to Health Canada. Complaints about consumer practices go to the provincial consumer protection authority.

What's the difference between off-label ketamine and SAP psilocybin or MDMA, in plain language? Off-label ketamine: Health Canada-approved medication (as anaesthetic), used by psychiatrists and other physicians for an off-label psychiatric indication under Canadian off-label prescribing principles. Legitimate, well-established. SAP psilocybin or MDMA: Health Canada has not approved these substances for clinical use, but the Special Access Program allows case-by-case access for patients with serious or life-threatening conditions where conventional therapy has failed. Both are legitimate clinical pathways; they sit in different regulatory positions.

Should I trust a clinic that is brand new? Newness is not disqualifying — every accredited clinic was new at some point — but a brand-new clinic should be able to demonstrate the same provincial accreditation, medical leadership, and clinical model that an established clinic does. Lack of accreditation is the disqualifying signal, not lack of operating history.

Compliance disclaimer

This article is educational. Psilocybin and MDMA are Schedule III and Schedule I controlled substances in Canada respectively; clinical access in Canada is via Health Canada's Special Access Program on a case-by-case basis. Ketamine is a Health Canada-approved anaesthetic; psychiatric use is off-label and within Canadian off-label prescribing principles. Esketamine (Spravato) is Health Canada-approved for treatment-resistant depression. Provincial accreditation requirements are described as of 2026-05-06 and may change; verify with the relevant provincial College for current requirements. Nothing in this article should be construed as a clinical recommendation for a specific individual or as a regulatory determination about a specific clinic.

Sources

1. College of Physicians and Surgeons of Ontario — Out-of-Hospital Premises Inspection Program (OHPIP): https://www.cpso.on.ca/en/Physicians/Your-Practice/Quality-in-Practice/Practice-Programs/OHPIP
2. College of Physicians and Surgeons of Alberta — Non-Sedation Health Facility (NSHF) Standards: https://cpsa.ca/physicians/standards-of-practice/
3. College of Physicians and Surgeons of British Columbia — Non-Hospital Medical and Surgical Facilities Accreditation Program (NHMSFAP): https://www.cpsbc.ca/programs/nhmsfap
4. Collège des médecins du Québec — Out-of-hospital medical facility framework: http://www.cmq.org/
5. College of Physicians and Surgeons of Saskatchewan — Non-Hospital Treatment Facility (NHTF) framework: https://www.cps.sk.ca/
6. College of Physicians and Surgeons of Manitoba — Accreditation framework (effective January 2026): https://cpsm.mb.ca/
7. Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access.html
8. Health Canada — Spravato Notice of Compliance and Product Monograph: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
9. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
10. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
11. Anand A, Mathew SJ, Sanacora G, et al. (2023). Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression (ELEKT-D). New England Journal of Medicine, 388(25):2315-2325. PMID: 37224135.
12. Dore J, Turnipseed B, Dwyer S, et al. (2019). Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. Journal of Psychoactive Drugs, 51(2):189-198. PMID: 30917760.

Related articles

• The Preparation Phase of Psychedelic-Assisted Therapy
• The Health Canada SAP Application Process — Complete Guide
• ATMA CENA's coordinated care model — how ATMA CENA layers onto an existing therapeutic relationship
• Insurance Coverage for Psychedelic-Assisted Therapy in Canada
• Edmonton Misericordia/Grey Nuns Public Ketamine
• Ketamine Therapy in Canada
• Psilocybin Therapy in Canada
• MDMA-Assisted Therapy in Canada

Last updated: 2026-05-06